SCHEMBL6601481

SCHEMBL6601481

CCOc1cc(-c2ccccc2)nn1CCOc1ccc(-c2cccnc2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.42
CYP11B2 P19099 3/20 0.42
CYP19A1 P11511 3/20 0.42
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
HPGD P15428 2/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GRM2 Q14416 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DHFR P00374 1/20 0.37
CREBBP Q92793 1/20 0.37
MAPT P10636 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805835 0.92 TP53 (0.43) MKNK1MKNK2
SCHEMBL6602658 0.91 HPGD (0.42) HPGDALDH1A1NPSR1LMNAL3MBTL1
SCHEMBL6805998 0.89 HPGD (0.41) HPGDALDH1A1NPSR1LMNAL3MBTL1
SCHEMBL6604163 0.86 S1PR4 (0.40) HPGDALDH1A1GRM2L3MBTL1CREBBP
SCHEMBL6601666 0.86 CYP11B1 (0.40) CYP11B1CYP11B2CYP19A1MKNK1MKNK2
SCHEMBL6607860 0.85 HPGD (0.40) HPGDALDH1A1LMNAL3MBTL1CREBBP
SCHEMBL6604189 0.85 MAPT (0.43) HPGDMAPK1KDM4EALDH1A1GRM2
SCHEMBL6603655 0.85 HPGD (0.38) HPGDALDH1A1L3MBTL1CREBBPMAPT
SCHEMBL6602333 0.85 HPGD (0.38) HPGDKDM4ENPSR1L3MBTL1CREBBP
SCHEMBL6613384 0.84 CYP3A4 (0.36) CYP11B1CYP11B2HPGDLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 CYP11B1 297/4885CYP11B2 179/4885CYP19A1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.